Breaking News

ICON Launches Early Phase Imaging Solution

By Gil Roth | October 17, 2012

Streamlined offering designed to support faster early phase decision making

ICON has launched a new medical imaging solution tailored to the unique requirements of early phase trials. This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research, according to the company. Enhanced decision making is then enabled by MIRA, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.

ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, senior vice president, Medical and Scientific Affairs, and Dr. Valerie Treyer, director, Medical and Scientific Affairs, who together have more than 45 years of experience in the management of medical image data used in clinical trials. The group will work closely with ICON Development Solutions.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” said Ted Gastineau, president, ICON Medical Imaging. “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems